Добавил:

Sekretar kiopkiopkiop18@yandex.ru t.me/Prokururor I Вовсе не секретарь, но почту проверяю Опубликованный материал нарушает ваши авторские права? Сообщите нам.

Вуз:

Ростовский Государственный Медицинский Университет

Предмет:

Медицина общая

Файл:

Книга_119_библиотеки_им_акад_М_И_Перельмана

.pdf

Скачиваний:

Добавлен:

15.09.2026

Размер:

10 Мб

Скачать

☆

<<< < Предыдущая 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 2223 / 2323

15 Immunotherapy forHead andNeck Cancer

https://t.me/med1917

213

References

Alexandrov, L.B., Nik-Zainal, S., Wedge, D.C., etal. (2013). Signatures of mutational processes

in human cancer. Nature, 500(7463), 415–421. https://doi.org/10.1038/nature12477 Brahmer, J. R., Lee, J. S., Ciuleanu, T. E., et al. (2023). Five-year survival outcomes with

nivolumab plus ipilimumab versus chemotherapy as rst-line treatment for metastatic non-

small- cell lung cancer in CheckMate 227. Journal of Clinical Oncology, 41(6), 1200–1212.

https://doi.org/10.1200/jco.22.01503

Burtness, B., Harrington, K.J., Greil, R., etal. (2019). Pembrolizumab alone or with chemother-

apy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma

of the head and neck (KEYNOTE-048): A randomised, open-label, phase 3 study. Lancet,

394(10212), 1915–1928. Chaturvedi, A.K., Engels, E.A., Pfeiffer, R.M., etal. (2011). Human papillomavirus and rising

oropharyngeal cancer incidence in the United States. Journal of Clinical Oncology, 29(32),

4294–4301. https://doi.org/10.1200/jco.2011.36.4596 Chung, C.H., Colevas, A.D. D., Adkins, D., etal. (2023). A phase 1 dose-escalation and expansion

study of CUE-101, a novel HPV16 E7-pHLA-IL2-Fc fusion protein, given as monotherapy

and in combination with pembrolizumab in patients with recurrent/metastatic HPV16+ head

and neck cancer. Journal of Clinical Oncology, 41(16_suppl), 6013. https://doi.org/10.1200/

JCO.2023.41.16_suppl.6013

Cohen, E.E. W., Soulières, D., Le Tourneau, C., etal. (2019). Pembrolizumab versus methotrexate,

docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma

(KEYNOTE-040): A randomised, open-label, phase 3 study. Lancet, 393(10167), 156–167.

https://doi.org/10.1016/s0140- 6736(18)31999- 8

FDA approves pembrolizumab for rst-line treatment of head and neck squamous cell carcinoma.

Accessed 8/18/2023.

fda- approves- pembrolizumab- rst- line- treatment- head- and- neck- squamous- cell- carcinoma

Ferris, R.L., Blumenschein, G., Fayette, J., etal. (2016). Nivolumab for recurrent squamous-cell

carcinoma of the head and neck. New England Journal of Medicine, 375(19), 1856–1867.

https://doi.org/10.1056/nejmoa1602252

Ferris, R. L., Haddad, R., Even, C., etal. (2020). Durvalumab with or without tremelimumab

in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE,

a randomized, open-label phase III study. Annals of Oncology, 31(7), 942–950. https://doi.

org/10.1016/j.annonc.2020.04.001

Ferris, R.L., Spanos, W.C., Leidner, R., etal. (2021). Neoadjuvant nivolumab for patients with

resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in

the CheckMate 358 trial. Journal for ImmunoTherapy of Cancer, 9(6). https://doi.org/10.1136/

jitc- 2021- 002568

Gillison, M.L., Blumenschein, G., Fayette, J., etal. (2022). Long-term outcomes with nivolumab

as rst-line treatment in recurrent or metastatic head and neck cancer: Subgroup analysis of

CheckMate 141. Oncologist, 27(2), e194–e198. https://doi.org/10.1093/oncolo/oyab036 Gormley, M., Creaney, G., Schache, A., Ingareld, K., & Conway, D.I. (2022). Reviewing the

epidemiology of head and neck cancer: Denitions, trends and risk factors. British Dental

Journal, 233(9), 780–786. Grimm, M.-O., Esteban, E., Barthélémy, P., et al. (2021). Efcacy of nivolumab/ipilimumab in

patients with initial or late progression with nivolumab: Updated analysis of a tailored approach

in advanced renal cell carcinoma (TITAN-RCC). Journal of Clinical Oncology, 39(15_suppl),

4576. https://doi.org/10.1200/JCO.2021.39.15_suppl.4576

Gyawali, B., Hey, S.P., & Kesselheim, A.S. (2019). Assessment of the clinical benet of cancer

drugs receiving accelerated approval. JAMA Internal Medicine, 179(7), 906–913. https://doi.

org/10.1001/jamainternmed.2019.0462

Haddad, R. I., Harrington, K., Tahara, M., et al. (2023). Nivolumab plus ipilimumab versus

EXTREME regimen as rst-line treatment for recurrent/metastatic squamous cell carcinoma of

https://doi.org/10.1016/s0140- 6736(19)32591- 7

https://www.fda.gov/drugs/resources- information- approved- drugs/

https://doi.org/10.1038/s41415- 022- 5166- x

214

https://t.me/med1917

the head and neck: The nal results of CheckMate 651. Journal of Clinical Oncology, 41(12),

2166–2180. https://doi.org/10.1200/jco.22.00332 Harrington, K. J., Ferris, R. L., Blumenschein, G., Jr., et al. (2017). Nivolumab versus stan-

dard, single-agent therapy of investigator’s choice in recurrent or metastatic squamous cell

carcinoma of the head and neck (CheckMate 141): Health-related quality-of-life results from

a randomised, phase 3 trial. The Lancet Oncology, 18(8), 1104–1115. https://doi.org/10.1016/

s1470- 2045(17)30421- 7

Harrington, K. J., Burtness, B., Greil, R., et al. (2023). Pembrolizumab With or Without

Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated

Results of the Phase III KEYNOTE-048 Study. Journal of Clinical Oncology, 41(4), 790–802.

https://doi.org/10.1200/jco.21.02508

Juloori, A., Agrawal, N., Cursio, J., etal. (2023). Neoadjuvant nivolumab, paclitaxel, and carbopla-

tin followed by response-stratied chemoradiation inlocoregionally advanced HPV negative

head and neck squamous cell carcinoma (HNSCC): The DEPEND trial. Journal of Clinical

Oncology, 41(16_suppl), 6007. https://doi.org/10.1200/JCO.2023.41.16_suppl.6007 Kim, H.S., Ham, J., Byeon, S., etal. (2015). The prevalence and prognostic relevance of PD-L1

expression in patients with HPV-negative and HPV-positive oropharyngeal cancer. Journal

of Clinical Oncology, 33(15_suppl), e14003. https://doi.org/10.1200/jco.2015.33.15_

suppl.e14003

Larkins, E., Blumenthal, G.M., Yuan, W., etal. (2017). FDA approval summary: Pembrolizumab

for the treatment of recurrent or metastatic head and neck squamous cell carcinoma with

disease progression on or after platinum-containing chemotherapy. The Oncologist, 22(7),

873–878. Lee, N.Y., Ferris, R. L., Psyrri, A., etal. (2021). Avelumab plus standard-of-care chemoradio-

therapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carci-

noma of the head and neck: A randomised, double-blind, placebo-controlled, multicentre, phase

3 trial. The Lancet Oncology, 22(4), 450–462. Machiels, J.P., Tao, Y., Burtness, B., etal. (2022). Primary results of the phase III KEYNOTE-412

study: Pembrolizumab (pembro) with chemoradiation therapy (CRT) vs placebo plus CRT for

locally advanced (LA) head and neck squamous cell carcinoma (HNSCC). Meeting abstract.

Annals of Oncology, 33(7), S1399–S1399. https://doi.org/10.1016/j.annonc.2022.08.029 Mandal, R., Şenbabaoğlu, Y., Desrichard, A., etal. (2016). The head and neck cancer immune

landscape and its immunotherapeutic implications. JCI Insight, 1(17). https://doi.org/10.1172/

jci.insight.89829

Masarwy, R., Kampel, L., Horowitz, G., Gutfeld, O., & Muhanna, N. (2021). Neoadjuvant PD-1/

PD-L1 inhibitors for Resectable head and neck cancer: A systematic review and meta-analysis.

JAMA Otolaryngology and Head and Neck Surgery, 147(10), 871–878. https://doi.org/10.1001/

jamaoto.2021.2191

Mehanna, H., Taberna, M., Von Buchwald, C., etal. (2023). Prognostic implications of p16 and

HPV discordance in oropharyngeal cancer (HNCIG-EPIC-OPC): A multicentre, multinational,

individual patient data analysis. The Lancet Oncology, 24(3), 239–251. https://doi.org/10.1016/

s1470- 2045(23)00013- x

Mito, I., Takahashi, H., Kawabata-Iwakawa, R., Ida, S., Tada, H., & Chikamatsu, K. (2021).

Comprehensive analysis of immune cell enrichment in the tumor microenvironment of

head and neck squamous cell carcinoma. Scientic Reports, 11(1). https://doi.org/10.1038/

s41598- 021- 95718- 9

Nivolumab for SCCHN.Accessed 8/18/2023. https://www.fda.gov/drugs/resources- information-

approved- drugs/nivolumab- scchn

Pai, S.I., & Westra, W. H. (2009). Molecular pathology of head and neck cancer: Implications

for diagnosis, prognosis, and treatment. Annual Review of Pathology: Mechanisms of Disease,

4(1), 49–70. https://doi.org/10.1146/annurev.pathol.4.110807.092158 Pembrolizumab (KEYTRUDA). Accessed 8/18/2023. https://www.fda.gov/drugs/resources-

information- approved- drugs/pembrolizumab- keytruda

Pster DG, & Sharon S. (n.d.). NCCN clinical practice guidelines in oncology– Head and neck can-

cers version 2.2023.

https://doi.org/10.1634/theoncologist.2016- 0496

https://doi.org/10.1016/s1470- 2045(20)30737- 3

https://www.nccn.org/professionals/physician_gls/pdf/head- and- neck.pdf

P. McGarrah et al.

15 Immunotherapy forHead andNeck Cancer

https://t.me/med1917

Pster, D.G., Haddad, R. I., Worden, F.P., et al. (2023). Biomarkers predictive of response to

pembrolizumab in head and neck cancer. Cancer Medicine, 12(6), 6603–6614. https://doi.

org/10.1002/cam4.5434

Price, K.A., Kaczmar, J.M., Worden, F.P., etal. (2023). Safety and efcacy of immune checkpoint

inhibitor (ICI) Naïve cohort from study of PDS0101 and pembrolizumab in HPV16-positive

head and neck squamous cell carcinoma (HNSCC). American Society of Clinical Oncology. Psyrri, A., Fayette, J., Harrington, K., etal. (2023). Durvalumab with or without tremelimumab

versus the EXTREME regimen as rst-line treatment for recurrent or metastatic squamous cell

carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study. Annals

of Oncology, 34(3), 262–274. https://doi.org/10.1016/j.annonc.2022.12.008 Rufn, A.T., Li, H., Vujanovic, L., Zandberg, D.P., Ferris, R.L., & Bruno, T.C. (2023). Improving

head and neck cancer therapies by immunomodulation of the tumour microenvironment.

Nature Reviews. Cancer, 23(3), 173–188. Schoenfeld, J. D., Hanna, G. J., Jo, V. Y., et al. (2020). Neoadjuvant nivolumab or nivolumab

plus ipilimumab in untreated Oral cavity squamous cell carcinoma: A phase 2 open-label

randomized clinical trial. JAMA Oncologia, 6(10), 1563–1570. https://doi.org/10.1001/

jamaoncol.2020.2955

SEER*Explorer. Accessed 8/17/2023.

tion.html

Stämpi, M.R., & Anderson, G.P. (2009). How cigarette smoke skews immune responses to pro-

mote infection, lung disease and cancer. Nature Reviews Immunology, 9(5), 377–384. https://

doi.org/10.1038/nri2530

Tosi, A., Parisatto, B., Menegaldo, A., etal. (2022). The immune microenvironment of HPV-

positive and HPV-negative oropharyngeal squamous cell carcinoma: A multiparametric quan-

titative and spatial analysis unveils a rationale to target treatment-naïve tumors with immune

checkpoint inhibitors. Journal of Experimental & Clinical Cancer Research, 41(1). https://doi.

org/10.1186/s13046- 022- 02481- 4

Veigas, F., Mahmoud, Y.D., Merlo, J., Rinerch, A., Rabinovich, G.A., & Girotti, M.R. (2021).

Immune checkpoints pathways in head and neck squamous cell carcinoma. Cancers, 13(5),

1018. https://doi.org/10.3390/cancers13051018

Vermorken, J.B., Mesia, R., Rivera, F., etal. (2008). Platinum-based chemotherapy plus cetux-

imab in head and neck cancer. The New England Journal of Medicine, 359(11), 1116–1127.

https://doi.org/10.1056/NEJMoa0802656

Wang, H.Q., Fu, R., Man, Q.W., Yang, G., Liu, B., & Bu, L. L. (2023). Advances in CAR-T

cell therapy in head and neck squamous cell carcinoma. Journal of Clinical Oncology, 12(6).

https://doi.org/10.3390/jcm12062173

Wolchok, J.D., Chiarion-Sileni, V., Gonzalez, R., etal. (2022). Long-term outcomes with nivolumab

plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma.

Journal of Clinical Oncology, 40(2), 127–137. https://doi.org/10.1200/jco.21.02229 Yu, G.-T., Bu, L.-L., Zhao, Y.-Y., etal. (2016). CTLA4 blockade reduces immature myeloid cells

in head and neck squamous cell carcinoma. OncoImmunology, 5(6), e1151594. https://doi.

org/10.1080/2162402x.2016.1151594

Zech, H.B., Moeckelmann, N., Boettcher, A., etal. (2020). Phase III study of nivolumab alone or

combined with ipilimumab as immunotherapy versus standard of care in resectable head and

neck squamous cell carcinoma. Future Oncology, 16(36), 3035–3043. https://doi.org/10.2217/

fon- 2020- 0595

Zou, X. L., Li, X. B., Ke, H., et al. (2021). Prognostic value of neoantigen load in immune

checkpoint inhibitor therapy for cancer. Frontiers in Immunology, 12, 689076. https://doi.

org/10.3389/mmu.2021.689076

Zuur, L., Vos, J.L., Elbers, J.B., etal. (2020). LBA40 neoadjuvant nivolumab and nivolumab plus

ipilimumab induce (near-) complete responses in patients with head and neck squamous cell

carcinoma: The IMCISION trial. Annals of Oncology, 31, S1169. https://doi.org/10.1016/j.

annonc.2020.08.2270

https://doi.org/10.1038/s41568- 022- 00531- 9

https://seer.cancer.gov/statistics- network/explorer/applica-

215

Chapter 16

https://t.me/med1917

Resources forPatients

YiyiYan andJessicaLee

Abstract The medical treatment landscape is continually changing. New medica-

tions and novel treatment modalities are emerging, thanks to ongoing research endeavors. Notably, immunotherapy has been a recent groundbreaking approach to treating cancer. Over the last few years, immunotherapy has been proven to alter the course of cancer care. It is quickly changing the ways we treat cancer and is bringing hope and optimism to cancer patients. Given the rapid advances in this eld, we strongly encourage our patients to engage in conversations about treatment options with their healthcare team to formulate an individualized treatment plan, including potential participation in ongoing clinical trials.

Keywords Resources · Immunotherapy · Education

The medical treatment landscape is continually changing. New medications and novel treatment modalities are emerging, thanks to ongoing research endeavors. Notably, immunotherapy has been a recent groundbreaking approach to treating cancer. Over the last few years, immunotherapy has been proven to alter the course of cancer care. It is quickly changing the ways we treat cancer and is bringing hope and optimism to cancer patients. Given the rapid advances in this eld, we strongly encourage our patients to engage in conversations about treatment options with their healthcare team to formulate an individualized treatment plan, including potential participation in ongoing clinical trials.

Immunotherapies to treat cancer have a unique side effect prole compared to other conventional cancer therapies, such as chemotherapy. It is important to have thorough patient education prior to the initiation of treatment. Equally vital is communicating with the healthcare team to inform the providers about the onset of side

Y. Yan Division of Medical Oncology, Mayo Clinic, Rochester, MN, USA

J. Lee (

Department of Medical Oncology, Mayo Clinic, Rochester, MN, USA e-mail: lee.jessica@mayo.edu

H. Dong, S. N. Markovic (eds.), The Basics of Cancer Immunotherapy,

https://doi.org/10.1007/978-3-031-59475-5_16

217© The Author(s), under exclusive license to Springer Nature Switzerland AG 2024

218

https://t.me/med1917

Y. Yan and J. Lee

effects or any new symptoms. Early recognition and prompt treatment of immunotherapy- related side effects are critical to ensure the best possible outcomes for patients. It is imperative not to self-medicate for common symptoms, such as diarrhea, as this may inadvertently exacerbate potential complications. The healthcare team will help you navigate the complexities of immunotherapy side effects.

Recognizing the limitations of this book in covering all aspects of cancer immunotherapy, we have compiled a list of additional resources for those seeking further information. Additionally, you can visit the website specic to your immunotherapy for more information. While the Internet can provide a lot of great resources and knowledge, we again encourage continuing conversations with your healthcare provider to address any specic questions related to your treatment.

We hope that these resources will assist you in gaining insights into cancer immunotherapy and its potential benets.

List of Resources

• American Cancer Society: www.cancer.org American Society of Clinical Oncology: www.cancer.net American Society of Hematology: www.hematology.org Cancer Research Institute: www.cancerresearch.org Chemocare: www.chemocare.com Clinical Trial Information: www.clinicaltrials.gov Intravenous Cancer Treatment Education: www.ivcanceredsheets.com Leukemia and Lymphoma Society: www.lls.org National Cancer Institute: www.cancer.gov National Comprehensive Cancer Network: www.nccn.org

Index

https://t.me/med1917

Adaptive immunities, 3, 4, 85, 102 Adjuvant, 8, 15, 17, 18, 21, 69, 72, 93–98,

103, 111–113, 117, 119, 129, 130, 132,

133, 143, 146–147, 150, 160 Anal cancer, 159 Antibody-drug conjugates (ADCs), 13, 72,

73, 135–138 Anti-PD-1, 7, 16, 88, 102, 111–117,

158–163, 184 Axicabtagene ciloleucel, 43, 47–49, 52

Biliary tract cancer (BTC), 161 Bi-specic T cell engagers (BiTEs), 13, 26–32 Bladder, 58, 147–152, 154 Blinatumomab, 26–30, 52 Breast cancer, 15, 17, 69–70, 97, 125–138 Breast cancer subtypes, 127–128, 131, 136 Brexucabtagene autoleucel, 43, 47–49

Cancer, 1, 11, 27, 33, 42, 57, 64, 82, 110, 126,

141, 157, 167, 180, 205, 217 CAR constructs, 42–46, 53 CAR-T cells, 7, 8, 43, 44, 46, 52, 53 CAR-T manufacturing, 44–46, 52 Cellular therapies, 41–53, 137, 138 Checkpoint inhibitors, 8, 76, 95, 98, 167–168,

209, 210, 212 Checkpoints, 5, 13, 36, 52, 73, 84, 111, 138,

173, 180, 207 Chemoimmunotherapies, 47, 64–76, 131–135

Chemoradiation, 113, 159, 160, 210, 211 Chemotherapy, 1, 11, 26, 36, 51, 59, 64, 82,

110, 126, 142, 158, 180, 217

Chimeric antigen receptors (CARs), 7, 8, 41,

43, 44, 46, 52 Ciltacabtagene autoleucel, 43, 47, 48, 50 Clinical trials, 8, 20, 21, 26, 27, 30, 47, 58, 59,

65, 66, 86–95, 97–99, 101, 114,

117–119, 130, 132, 135, 136, 144–146,

150, 151, 153, 154, 158, 159, 168, 174,

207–211, 217 Colorectal cancer (CRC), 15, 16, 72, 157–160 Combination therapies, 9, 67, 73, 75, 76,

89–90, 96, 102, 144, 145, 153, 171,

173, 180 Cytokine release syndrome (CRS), 30–31,

36, 50, 51 Cytotoxic T lymphocyte-associated-protein 4

(CTLA-4), 6, 14–18, 21, 52, 84, 87,

89–91, 100, 103, 146, 161, 180, 182,

183, 190, 199, 207, 209, 210

Early-stage breast cancer, 128, 129, 134 Education, 217 Enfortumab, 151 Epcoritamab, 29 Esophageal cancer, 159 Extensive stage, 110, 118, 120

GI cancer, 72, 157, 159, 160, 162, 163 Glotamab, 29

charitable corporation 2024 H. Dong, S. N. Markovic (eds.), The Basics of Cancer Immunotherapy,

https://doi.org/10.1007/978-3-031-59475-5

220

https://t.me/med1917

Index

Head and neck cancer, 71–72, 205–212 Head and neck squamous cell carcinoma

(HNSCC), 71, 72, 206–212 HER2 negative breast cancer, 137 Herpes simplex virus (HSV), 58, 184,

197, 200 Human papilloma virus (HPV), 159, 206, 207

Idecabtagene vicleucel, 43, 47, 48, 50 Immune checkpoint inhibitors (ICIs), 7, 8,

11–21, 27, 34, 36, 42, 64, 65, 68,

70–72, 76, 83, 86, 89–94, 99–103, 111,

113–115, 117–120, 136, 137, 144, 149,

158, 167, 173, 174, 180–196, 200 Immune checkpoints, 5, 6, 13, 14, 16–18, 36,

73, 84, 85, 89, 94, 96, 98, 100,

110–120, 138, 180, 207 Immune effector cell-associated neurotoxicity

syndrome (ICANS), 31, 51 Immune escape, 27, 42, 84 Immune-related adverse events (irAEs), 9,

19–21, 36, 174, 180–196, 201, 202 Immunosuppression, 20, 21, 64, 68, 84–85,

97, 102, 168, 170, 172, 173, 175, 202 Immunotherapy, 1, 11, 42, 59, 64, 110, 126,

142, 158, 180, 206, 217 Infrastructure for TIL therapy, 33–36 Innate immunity, 3 Interleukin 2 (IL-2), 33–36, 86–87, 99,

100, 144 Intralesional injection, 58 In-transit disease, 59 Ipilimumab, 13–16, 20, 34, 67, 70, 71, 74,

87–89, 92–95, 97, 98, 100, 114–116,

137, 145, 146, 151, 153, 185,

199, 210

Lung adenocarcinoma, 110 Lung cancer, 6, 65–69, 74, 75, 110–120, 158 Lung squamous cell carcinoma, 110 Lymphocyte activation gene 3 (LAG-3),

16–18, 52, 85, 90, 98, 180, 201

Lymphodepleting therapy, 51

Melanoma, 13, 27, 33, 58, 70, 82, 134, 158 Metastatic, 14, 30, 34, 66, 82, 116, 128, 142,

175, 186, 208 Metastatic breast cancer, 126, 134, 137 Metastatic melanomas, 16, 17, 34, 70, 74, 82,

85, 87–91, 99, 100, 103 Monoclonal antibodies (mAb), 12, 28, 45, 46,

48, 72, 87, 88, 90, 99, 135–138, 160,

161, 173, 208 Mosunetuzumab, 29 Mouth cancer, 205 Muscle-invasive, 148

Neoadjuvant, 15, 17, 18, 21, 69, 72, 96–99,

103, 111–112, 129, 130, 132, 133,

150, 160 Nivolumab, 14–18, 66, 67, 87–92, 95–98, 111,

113, 115, 116, 144–146, 150–154, 159,

160, 174, 201, 208–210 Non-small cell lung cancer (NSCLC), 15–17,

65–67, 69, 74, 75, 102, 110–120, 187 Novel immune checkpoints, 18, 21

Oncolytic virus, 58, 91 Oral cavity cancer, 205, 208 Organ rejection, 20, 168 Oropharynx cancers, 208

KEYNOTE-355, 69, 134 KEYNOTE-522, 69, 132, 133 Kidney, 15, 16, 19, 21, 141–147, 150, 151,

168–173, 175, 189, 197, 199, 201

Larynx cancer, 205 Limited stage, 94, 110, 118 Lisocabtagene maraleucel, 43, 47–49 Liver cancer, 15–17, 160–161

Pancreatic cancer, 72, 161–162 PD-L1 TPS, 119 Pembrolizumab, 16, 66, 87–89, 112, 132, 144,

158, 201, 208 Penile, 152–154 Programmed death ligand 1 (PD-L1), 6, 16,

27, 42, 66, 84, 111, 131, 144, 158, 173,

180, 207 Programmed death receptor 1 (PD-1), 6, 14,

52, 64, 84, 111, 131, 144, 158, 180, 207

Index

https://t.me/med1917

221

Prostate, 71, 148, 152–154

Relatlimab, 16–18, 90, 92, 98, 201 Resistance, 45, 51–52, 65, 70, 117, 120,

162, 211 Resources, 218 Risk factors, 110, 126, 142, 143, 147, 160, 206

Small cell lung cancer (SCLC), 16, 17, 67–69,

75, 110, 111, 118–120 Solid organ transplants, 20–21, 167–175 Stomach cancer, 159–160

T cell immunoglobulin and ITM domain

(TIGIT), 18, 69, 85, 102–103 T cells, 4, 13, 26, 33, 42, 64, 131, 144,

167, 206 T cell signaling, 27, 42–44

Talimogene laherparepvec (T-VEC), 58,

59, 91, 137 Tebentafusp, 28, 93 Teclistamab, 30 Testicular, 152–154 Throat cancer, 205 Tisagenlecleucel, 43, 47, 48 Transplantation, 20, 30, 160, 168, 173, 174 Triple negative breast cancer (TNBC), 17, 69,

70, 126–138 Tumor-inltrating lymphocytes (TILs), 33–37,

82, 83, 86–87, 99–101, 130, 131,

158, 159

Unresectable, 28, 30, 34, 58, 69, 86–95, 98,

99, 113, 143, 148, 151–152 Urothelial, 15–17, 71, 142, 147–152, 154

Vaccines, 7, 8, 87, 99, 101–102, 137, 138,

153, 212

<<< < Предыдущая 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 2223 / 2323

Соседние файлы в папке Библиотека им академика М.И. Перельмана

#
15.09.202617 Мб0Книга_1182_Библиотеки_им_академика_М_И_Перельмана.pdf
#
15.09.202617 Мб0Книга_1183_Библиотеки_им_академика_М_И_Перельмана.pdf
#
15.09.202617 Мб0Книга_1184_Библиотеки_им_академика_М_И_Перельмана.pdf
#
15.09.202617 Мб0Книга_1185_Библиотеки_им_академика_М_И_Перельмана.pdf
#
15.09.202617 Мб0Книга_1186_Библиотеки_им_академика_М_И_Перельмана.pdf
#
15.09.202610 Мб0Книга_119_библиотеки_им_акад_М_И_Перельмана.pdf
#
15.09.202617 Мб0Книга_1190_Библиотеки_им_академика_М_И_Перельмана.pdf
#
15.09.202617 Мб0Книга_1192_Библиотеки_им_академика_М_И_Перельмана.pdf
#
15.09.202617 Мб0Книга_1193_Библиотеки_им_академика_М_И_Перельмана.pdf
#
15.09.202617 Мб0Книга_1196_Библиотеки_им_академика_М_И_Перельмана.djvu
#
15.09.202617 Мб0Книга_1198_Библиотеки_им_академика_М_И_Перельмана.djvu